Further, Venetoclax, which is a recent addition to the therapeutic repertoire in AML, targets LSCs through two independent mechanisms: firstly, through BCL-2 inhibition, and secondly, via suppression of metabolism and oxidative phosphorylation [44–46]. This evidence concerns the gene BCL2 and acute myeloid leukemia.